I can maybe provide a very quick answer from our perspective.
We're not advocating the patent extension period. What we're talking about is a separate issue; that is, data protection for new uses. I don't really have anything I can provide you on the costs that might accrue to provinces for extending the patent of a prescription drug that's on their formulary. We're talking about how you actually provide some incentive for establishing new uses for already established safe products that will give a greater impetus to lowering the costs.
If there were 20 candidates for switch and ten of them were to switch, you could lower the costs of provincial health care considerably because those would come off formulary and they would lower in price, even if you had more than one year's data protection—and the only reason we're saying one year is that we have no years now.